keyword
MENU ▼
Read by QxMD icon Read
search

biomarker lung cancer

keyword
https://www.readbyqxmd.com/read/30516882/dna-methylation-analysis-of-selected-genes-for-the-detection-of-early-stage-lung-cancer-using-circulating-cell-free-dna
#1
Zhiping Yang, Weibo Qi, Li Sun, Hui Zhou, Biliu Zhou, Yi Hu
BACKGROUND: Lung cancer is still the deadliest cancer in the world, but early diagnosis cannot be achieved because of the limitations of diagnostic methods. DNA methylation has been proven to be a potentially powerful tool for cancer detection and diagnosis over the past decade. OBJECTIVES: We explored whether free DNA methylation in plasma can be a reliable biomarker for noninvasive lung cancer detection. MATERIAL AND METHODS: We detected the methylation of 8 genes in plasma-free DNA of patients with pulmonary space-occupying lesions using real-time quantitative methylation-specific polymerase chain reaction (QMSP)...
December 5, 2018: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/30515265/loss-of-mir-198-and-206-during-primary-tumor-progression-enables-metastatic-dissemination-in-human-osteosarcoma
#2
Steven Georges, Lidia Rodriguez Calleja, Camille Jacques, Melanie Lavaud, Brice Moukengue, Fernando Lecanda, Thibaut Quillard, Marta Tellez Gabriel, Pierre-François Cartron, Marc Baud'huin, François Lamoureux, Dominique Heymann, Benjamin Ory
The metastatic dissemination is a complex multistep process by which tumor cells from a primary site enter into the systemic circulation to finally spread at distant sites. Even if this mechanism is rare at the tumor level, it remains the major cause of Osteosarcoma-patients' relapse and mortality. MicroRNAs (miRNAs) have recently been described as novel epigenetics' genes' expression regulators actively implicated in cancer progression and dissemination. The understanding of their implication in the metastatic spreading could help clinicians to improve the outcome of osteosarcoma...
November 6, 2018: Oncotarget
https://www.readbyqxmd.com/read/30514666/the-association-between-imaging-features-of-tsct-and-the-expression-of-pd-l1-in-patients-with-surgical-resection-of-lung-adenocarcinoma
#3
Tong Wu, Fei Zhou, Adiilah K Soodeen-Lalloo, Xing Yang, Yingran Shen, Xi Ding, Jinpeng Shi, Jie Dai, Jingyun Shi
OBJECTIVES: Programmed death-ligand 1 (PD-L1) expression might serve as a predictive biomarker for immune checkpoint inhibitors in lung cancer. However, the relationship between PD-L1 expression and imaging features of lung cancer has not been fully understood. PATIENTS AND METHODS: A total of 350 patients with pathologically confirmed adenocarcinoma who received surgical treatment and had preoperative thin section computed tomography (CT) examination were included...
November 14, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30514297/sox30-specially-prevents-wnt-signaling-to-suppress-metastasis-and-improve-prognosis-of-lung-adenocarcinoma-patients
#4
Fei Han, Ming-Qian Zhang, Wen-Bin Liu, Lei Sun, Xiang-Lin Hao, Li Yin, Xiao Jiang, Jia Cao, Jin-Yi Liu
BACKGROUND: Different histological subtypes of non-small cell lung cancer (NSCLC) show different molecular characteristics and responses to therapeutic strategy. Identification of specific gene, clarification of its special roles and molecular mechanisms are crucial for developing new therapeutic approach for particular subtype patients. METHODS: Surgical specimens of 540 NSCLC patients were recruited. Immunohistochemistry was used to detect SOX30 expression, and correlations with clinical parameters were analyzed...
December 4, 2018: Respiratory Research
https://www.readbyqxmd.com/read/30512237/overexpression-of-kcnj4-correlates-with-cancer-progression-and-unfavorable-prognosis-in-lung-adenocarcinoma
#5
Xiao-Yan Wu, Xue-Yan Yu
KCNJ4 (potassium voltage-gated channel subfamily J member 4) belongs to the inward rectifier potassium channel family, which is inhibited by novel anticancer agents. However, the biologic significance of KCNJ4 in lung adenocarcinoma (LADC) is largely unknown. Therefore, in this study, we evaluated the expression, clinical correlation, and prognostic value of KCNJ4 in LADC and normal lung tissues according to data from The Cancer Genome Atlas datasets. A small interfering RNA (siRNA)-mediated technology was used to inhibit the expression level of KCNJ4...
December 4, 2018: Journal of Biochemical and Molecular Toxicology
https://www.readbyqxmd.com/read/30510441/the-prognostic-impact-of-neutrophil-to-lymphocyte-ratio-in-advanced-non-small-cell-lung-cancer-patients-treated-with-egfr-tki
#6
Thang Thanh Phan, Toan Trong Ho, Hue Thi Nguyen, Hang Thuy Nguyen, Thu Bich Tran, Son Truong Nguyen
Purpose: To identify and clarify the roles of inflammatory markers in prognosis for advanced non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitor (TKI). Patients and methods: One hundred and twelve adenocarcinoma, clinical stage IV, NSCLC patients with either EGFR exon 19 deletion (E19del) or EGFR exon 21 L858R substitution mutation (L858R) were selected for this study. The blood cell count at different stages of treatment was used to calculate the inflammatory markers...
2018: International Journal of General Medicine
https://www.readbyqxmd.com/read/30510432/trim37-targets-akt-in-the-growth-of-lung-cancer-cells
#7
Shumin Dong, Xueqin Pang, Haijun Sun, Chunluan Yuan, Chuanyong Mu, Shiying Zheng
Background: TRIM37 is an ubiquitin E3 ligase. Growing evidence has demonstrated the high value of TRIM37 as a potential biomarker for diagnosis of certain cancers. However, the biological function of TRIM37 in lung cancer is still unknown. Materials and methods: In order to gain a deep insight into the function of TRIM37 in lung cancer cells, in the present study lentiviral vector was used to mediate RNA interference and overexpression of TRIM37 in lung cancer cells (H292, H358, and H1299)...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/30509097/circulating-tumor-cells-in-lung-carcinogenesis-minireview
#8
H Skovierova, E Vidomanova, M Skoviera, B Tothova, E Halasova, J Strnadel
Metastasis development causes death in over 90% of cancer patients, and understanding the underlying biological features has long been hindered by difficulties in studying the widespread cancerous lesions and the absence of reliable methods of isolating and detecting viable metastatic cells during disease progression. These problems have an adverse impact on developing new agents capable of blocking cancer spread. Circulating tumor cells (CTCs) have a crucial role in carcinogenesis, and this review presents advanced understanding of the characteristics of CTCs and CTC cluster metastatic properties...
August 9, 2018: Neoplasma
https://www.readbyqxmd.com/read/30508306/promising-efficacy-of-shr-1210-a-novel-anti-programmed-cell-death-1-antibody-in-patients-with-advanced-gastric-and-gastroesophageal-junction-cancer-in-china
#9
Jing Huang, Hongnan Mo, Weilong Zhang, Xuelian Chen, Dong Qu, Xi Wang, Dawei Wu, Xingyuan Wang, Bo Lan, Beibei Yang, Pei Wang, Bo Zhang, Qing Yang, Yuchen Jiao, Binghe Xu
BACKGROUND: The clinical response to anti-programmed cell death 1 (PD-1) antibodies in patients with advanced gastric and gastroesophageal junction (GEJ) cancer in China has not been reported. METHODS: This study evaluated the efficacy and safety of SHR-1210, an anti-PD-1 antibody, in patients with advanced gastric/GEJ cancer in a phase 1 trial. The associations between candidate biomarkers (programmed death ligand 1 [PD-L1] expression, mismatch repair status, tumor mutation load, and lactate dehydrogenase [LDH] levels) and the efficacy of SHR-1210 were also explored...
December 3, 2018: Cancer
https://www.readbyqxmd.com/read/30508167/prognostic-value-of-neutrophil-to-lymphocyte-ratio-in-lung-metastasectomy-for-colorectal-cancer
#10
Stéphane Renaud, Joseph Seitlinger, David St-Pierre, Richard Garfinkle, Yaseen Al Lawati, Francesco Guerrera, Enrico Ruffini, Pierre-Emmanuel Falcoz, Gilbert Massard, Lorenzo Ferri, Jonathan Spicer
OBJECTIVES: Neutrophil to lymphocyte ratio (NLR) has been shown to be a promising biomarker in several cancers. Prognostic biomarkers are still needed to define good candidates for lung metastasectomy for colorectal cancer. We aimed to evaluate the role of NLR. METHODS: Data from 574 patients who underwent lung metastasectomy for colorectal cancer in 3 departments of thoracic surgery from 2004 to 2014 were retrospectively reviewed. Overall survival (OS) and the time to pulmonary recurrence (TTPR) were the main end points...
December 1, 2018: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/30506837/mnx1-as1-is-a-novel-biomarker-for-predicting-clinical-progression-and-poor-prognosis-in-lung-adenocarcinoma
#11
Ronghua Yang, Lei Wang, Minghui Han
Motor neuron and pancreas homeobox 1-antisense RNA1 (MNX1-AS1) is a novel long noncoding RNA and has been suggested to be overexpressed in human ovarian cancer and glioma. The role of MNX1-AS1 in lung cancer was still unknown. In our study, we observed levels of MNX1-AS1 expression through analyzing The Cancer Genome Atlas and found MNX1-AS1 expression was highly expressed in lung adenocarcinoma tissues compared with normal lung tissues, but there was no statistical difference between lung squamous cell carcinoma tissues and normal lung tissues...
December 2, 2018: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/30505714/challenges-and-unanswered-questions-for-the-next-decade-of-immune-oncology-research-in-nsclc
#12
REVIEW
Niki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell
Over the last 20 years there have been great advances in the treatment of lung cancer. Immune checkpoint blockade together with targeted therapies have provided oncologists with the means to improve survival of non-small cell lung cancer (NSCLC) and patients with a better quality of life and therapies with manageable toxicity. Maybe in a short period of time the possibility of a cure in metastatic NSCLC will be raised. Therefore, continued research into new drugs, biomarkers and especially combination therapies is necessary in order to expand the clinical benefit of the current treatments to a broader population of NSCLC patients...
December 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30505713/predictive-markers-for-anti-pd-1-pd-l1-therapy-in-non-small-cell-lung-cancer-where-are-we
#13
REVIEW
Matthew Evans, Brendan O'Sullivan, Matthew Smith, Philippe Taniere
The selection of patients for immunotherapy remains challenging given the lack of highly specific and highly sensitive biomarkers. Nevertheless, it is essential that testing laboratories are able to fulfil licencing criteria by providing the tests which have been validated as providing useful predictive information. Programmed cell death protein 1 (PD-1) expression assessment is now established in routine practice, although the situation regarding the selection of a particular assay remains complex, and testing protocols are likely to change in future...
December 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30505711/measuring-tumor-mutation-burden-in-non-small-cell-lung-cancer-tissue-versus-liquid-biopsy
#14
REVIEW
Francesca Fenizia, Raffaella Pasquale, Cristin Roma, Francesca Bergantino, Alessia Iannaccone, Nicola Normanno
The introduction in the clinic of immune checkpoint inhibitors (IOs) has represented an important improvement for the treatment of patients with advanced non-small cell lung cancer (NSCLC). These drugs have shown a higher activity as compared with chemotherapy in both first- and second-line of treatment, with some patients experiencing a long-lasting response. More recently, combinations of IOs have entered clinical trials in different tumor types including NSCLC. Nevertheless, IOs are active only in a subgroup of patients and biomarkers for appropriate patients' selection are urgently needed to offer the patients an effective therapy, and also to manage the costs...
December 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30505709/clinical-utility-of-tumor-mutational-burden-in-patients-with-non-small-cell-lung-cancer-treated-with-immunotherapy
#15
REVIEW
Lizza E Hendriks, Etienne Rouleau, Benjamin Besse
Anti-programmed death (ligand)-1 [anti-PD-(L)1] therapies such as pembrolizumab, nivolumab or atezolizumab have become standard of care for non-small cell lung cancer (NSCLC) patients either in first line or beyond. PD-L1 expression level allows enriching the treated population with responders, but it is still not an optimal biomarker. Even in patients with PD-L1 tumor proportion score (TPS) levels of ≥50% treated with first line pembrolizumab overall response rate (ORR) is only 44.8% and overall survival at one year is 70%...
December 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30505708/the-clinical-utility-of-tumor-mutational-burden-in-non-small-cell-lung-cancer
#16
REVIEW
Laurent Greillier, Pascale Tomasini, Fabrice Barlesi
Despite advances made during the last two decades, lung cancer remains the leading cause of cancer-related death worldwide. Recently, immune checkpoint inhibitors (ICIs) became available for the treatment of advanced non-small cell lung cancer (NSCLC) patients. Although ICIs showed a survival advantage in comparison with chemotherapy in the second and first-line setting, overall response rate is only around 20% and a large proportion of patients will undergo disease progression within the first weeks of treatment...
December 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30505707/tumor-mutational-burden-assessment-as-a-predictive-biomarker-for-immunotherapy-in-lung-cancer-patients-getting-ready-for-prime-time-or-not
#17
REVIEW
Simon Heeke, Paul Hofman
The emergence of immunotherapy as a first- or second-line of treatment has revolutionized the therapeutic management of lung cancer patients. However, not all lung cancer patients receive the same benefit from this treatment, leading to limitations in the number of patients who can receive anti-PD-1/PD-L1 checkpoint inhibitors because some secondary toxicity has been associated with immunotherapy, and because some patients would benefit more from chemotherapy. In this context, the selection of patients is currently based on PD-L1 immunohistochemistry (IHC), specifically on the percentage of PD-L1 positive tumor cells...
December 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30505706/a-scalable-solution-for-tumor-mutational-burden-from-formalin-fixed-paraffin-embedded-samples-using-the-oncomine-tumor-mutation-load-assay
#18
Ruchi Chaudhary, Luca Quagliata, Jermann Philip Martin, Ilaria Alborelli, Dinesh Cyanam, Vinay Mittal, Warren Tom, Janice Au-Young, Seth Sadis, Fiona Hyland
Background: Tumor mutational burden (TMB) is an increasingly important biomarker for immune checkpoint inhibitors. Recent publications have described strong association between high TMB and objective response to mono- and combination immunotherapies in several cancer types. Existing methods to estimate TMB require large amount of input DNA, which may not always be available. Methods: In this study, we develop a method to estimate TMB using the Oncomine Tumor Mutation Load (TML) Assay with 20 ng of DNA, and we characterize the performance of this method on various formalin-fixed, paraffin-embedded (FFPE) research samples of several cancer types...
December 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/30504389/chronic-inflammation-as-a-potential-predictive-factor-of-nivolumab-therapy-in-non-small-cell-lung-cancer
#19
Martin Svaton, Milada Zemanova, Jana Skrickova, Lenka Jakubikova, Vitezslav Kolek, Juraj Kultan, Leona Koubkova, Alzbeta Bejckova, Frantisek Salajka, Michal Hrnciarik, Bohuslav Melichar, David Vrana, Marek Konecny, Renata Chloupkova, Milos Pesek
AIM: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. PATIENTS AND METHODS: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. RESULTS: Among clinical parameters, histology was significantly associated with progression-free survival...
December 2018: Anticancer Research
https://www.readbyqxmd.com/read/30504086/serological-assessment-of-activated-fibroblasts-by-alpha-smooth-muscle-actin-%C3%AE-sma-a-noninvasive-biomarker-of-activated-fibroblasts-in-lung-disorders
#20
Signe Holm Nielsen, Nicholas Willumsen, Diana Julie Leeming, Samuel Joseph Daniels, Susanne Brix, Morten Asser Karsdal, Federica Genovese, Mette Juul Nielsen
OBJECTIVES: Remodeling of the extracellular matrix (ECM) is a key event in different lung disorders, such as fibrosis and cancer. The most common cell type in the connective tissue is fibroblasts, which transdifferentiate into myofibroblasts upon activation. All myofibroblasts express α-SMA, which has been found to be upregulated in lung fibrosis and cancer. We evaluated the potential of α-SMA as a noninvasive biomarker of activated fibroblasts in lung fibrosis and cancer. METHODS: A monoclonal antibody was raised against the N-terminal of α-SMA, and a novel competitive enzyme-linked immunosorbent assay (ELISA) measuring α-SMA was developed and technically characterized...
November 29, 2018: Translational Oncology
keyword
keyword
158958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"